-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) Tops Q3 EPS by 9c
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) Tops Q1 EPS by 17c
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) PT Lowered to $60 at Oppenheimer
-
-
-
-
-
-
-
Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress
-
-
-
-
-
-
-
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress
-
-
-
-
-
-
-
Intellia Therapeutics (NTLA) Misses Q2 EPS by 8c, beats revenue
-
-
-
-
-
-
-
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
-
1,197,273 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

